US 12,227,776 B2
Engineered cascade components and cascade complexes
Peter Sean Cameron, San Francisco, CA (US); Scott David Gradia, Albany, CA (US); Sanne Eveline Klompe, New York, NY (US); Samuel Henry Sternberg, New York, NY (US); and Matthew Scott Thompson, San Francisco, CA (US)
Assigned to Caribou Biosciences, Inc., Berkeley, CA (US)
Filed by CARIBOU BIOSCIENCES, INC., Berkeley, CA (US)
Filed on Dec. 11, 2020, as Appl. No. 17/120,081.
Application 17/120,081 is a continuation of application No. PCT/US2019/036864, filed on Jun. 12, 2019.
Claims priority of provisional application 62/684,735, filed on Jun. 13, 2018.
Claims priority of provisional application 62/807,717, filed on Feb. 19, 2019.
Prior Publication US 2021/0102183 A1, Apr. 8, 2021
Int. Cl. C12N 9/22 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/00 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12N 15/90 (2006.01)
CPC C12N 9/22 (2013.01) [C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/00 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/902 (2013.01); C12N 15/907 (2013.01); C07K 2319/00 (2013.01); C07K 2319/09 (2013.01); C07K 2319/21 (2013.01); C07K 2319/22 (2013.01); C07K 2319/50 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)] 15 Claims
 
1. An engineered Type I CRISPR-Cas effector composition comprising:
a Type I CRISPR-Cas subunit protein;
a Type I guide polynucleotide; and
an engineered Type I CRISPR mCas3 (mCas3) protein, wherein the engineered mCas3 protein is selected from the group consisting of Pseudomonas sp. S-6-2 mCas3 proteins D448A mCas3, D75A mCas3, and D448A D75A mCas3.